Skip to main content

Table 2 Baseline characteristics of patients in the COMBI-v and coBRIM studies

From: Indirect treatment comparison of dabrafenib plus trametinib versus vemurafenib plus cobimetinib in previously untreated metastatic melanoma patients

  COMBI-v coBRIM
D + T V V + placebo V + C
Intent-to-treat population 352 352 248 247
Age, median (range), yr 55(18–91) 54(18–88) 55(25–85) 56(23–88)
Male sex, no. (%) 208(59) 180(51) 140(56) 146(59)
ECOG score, no./total no. (%)
 0 248/350(71) 248/352(70) 164/244(67) 184/243(76)
 1 102/350(29) 14/352(30) 80/244(33) 58/243(24)
 2 0/350 0/352 0/244 1/243(<1)
Metastatic status, no./total no. (%)
 M0 14/351(4) 26/351(7) 13(5) 21(9)
 M1a 55/351(16) 50/351(14) 40(16) 40(16)
 M1b 61/351(17) 67/351(19) 42(17) 40(16)
 M1c 221/351(63) 208/351(59) 153(62) 146(59)
Elevated LDH, no. /total no. (%) 118/351(34) 114/352(32) 104/242(43) 112/242(46)
BRAF mutation, no. /total no. (%)
 V600E 312/346(90) 317/351(90) 174/206(84) 170/194(88)
 V600K 34/346(10) 34 /351(10) 32/206(16) 24/194(12)
  1. D + T dabrafenib plus trametinib, ECOG Eastern Cooperative Oncology Group, LDH lactate dehydrogenase, V vemurafenib, V + C vemurafenib plus cobimetinib